Skip to main content
Erschienen in: Digestive Diseases and Sciences 7/2019

09.05.2019 | Invited Review

Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease

verfasst von: Mirabella Zhao, Johan Burisch

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Crohn’s disease and ulcerative colitis constitute two major subgroups of inflammatory bowel diseases (IBD), a group of complex polygenic diseases characterized by chronic and progressive inflammation in the gastrointestinal tract. In recent years, methodological advances in genetic analysis have greatly expanded our understanding of the genetic background of IBD. So far, more than 240 genetic risk loci have been identified for IBD. However, these risk alleles explain less than 30% of the susceptibility to disease development, suggesting that environmental factors contribute considerably. The increasing occurrence of IBD in Eastern countries following their ‘westernization’, as well as the increased risk of disease among those who migrate to high-incidence regions, also suggest that the environment is key in the pathogenesis of IBD. In this review, we summarize the current evidence on the role of genetic and environmental factors in the susceptibility to, and disease course of, IBD, and we suggest how these findings might be applied to clinical practice.
Literatur
1.
Zurück zum Zitat Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohnʼs disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol. 1999;94:3236–3238.CrossRefPubMed Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohnʼs disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol. 1999;94:3236–3238.CrossRefPubMed
2.
Zurück zum Zitat Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol. 2015;110:564–571.CrossRefPubMed Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol. 2015;110:564–571.CrossRefPubMed
3.
Zurück zum Zitat Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.CrossRefPubMedPubMedCentral Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.CrossRefPubMedPubMedCentral Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–1125.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.CrossRefPubMedPubMedCentral Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43–55.CrossRefPubMed Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43–55.CrossRefPubMed
8.
Zurück zum Zitat Davies JM, Abreu MT. The innate immune system and inflammatory bowel disease. Scand J Gastroenterol. 2015;50:24–33.CrossRefPubMed Davies JM, Abreu MT. The innate immune system and inflammatory bowel disease. Scand J Gastroenterol. 2015;50:24–33.CrossRefPubMed
9.
Zurück zum Zitat Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62:1556–1565.CrossRefPubMed Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62:1556–1565.CrossRefPubMed
10.
Zurück zum Zitat Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut. 2004;53:987–992.CrossRefPubMedPubMedCentral Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut. 2004;53:987–992.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Bank S, Skytt Andersen P, Burisch J, et al. Polymorphisms in the Inflammatory Pathway Genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG Are Associated with Susceptibility of Inflammatory Bowel Disease in a Danish Cohort. Heimesaat MM, ed. PLoS One. 2014;9:e98815. Bank S, Skytt Andersen P, Burisch J, et al. Polymorphisms in the Inflammatory Pathway Genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG Are Associated with Susceptibility of Inflammatory Bowel Disease in a Danish Cohort. Heimesaat MM, ed. PLoS One. 2014;9:e98815.
12.
Zurück zum Zitat Heliö T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558–562.CrossRefPubMedPubMedCentral Heliö T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558–562.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–167.CrossRefPubMedPubMedCentral Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–167.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Weersma RK, Zhernakova A, Nolte IM, et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol. 2008;103:621–627.CrossRefPubMed Weersma RK, Zhernakova A, Nolte IM, et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol. 2008;103:621–627.CrossRefPubMed
15.
Zurück zum Zitat Wang C, Yuan X, Ma E, et al. NOD2 is dispensable for ATG16L1 deficiency-mediated resistance to urinary tract infection. Autophagy. 2014;10:331–338.CrossRefPubMed Wang C, Yuan X, Ma E, et al. NOD2 is dispensable for ATG16L1 deficiency-mediated resistance to urinary tract infection. Autophagy. 2014;10:331–338.CrossRefPubMed
16.
Zurück zum Zitat Glas J, Konrad A, Schmechel S, et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn’s disease in the german population. Am J Gastroenterol. 2008;103:682–691.CrossRefPubMed Glas J, Konrad A, Schmechel S, et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn’s disease in the german population. Am J Gastroenterol. 2008;103:682–691.CrossRefPubMed
17.
Zurück zum Zitat Ng SC, Tsoi KKF, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1164–1176.CrossRefPubMed Ng SC, Tsoi KKF, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1164–1176.CrossRefPubMed
18.
Zurück zum Zitat Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology. 2000;119:1740–1744.CrossRefPubMed Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology. 2000;119:1740–1744.CrossRefPubMed
19.
Zurück zum Zitat Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease. Gut. 2009;58:1121–1127.CrossRefPubMed Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease. Gut. 2009;58:1121–1127.CrossRefPubMed
20.
Zurück zum Zitat Elding H, Lau W, Swallow DM, Maniatis N. Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease. Am J Hum Genet. 2011;89:798–805.CrossRefPubMedPubMedCentral Elding H, Lau W, Swallow DM, Maniatis N. Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease. Am J Hum Genet. 2011;89:798–805.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Diaz-Gallo L-M, Espino-Paisán L, Fransen K, et al. Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitis. Inflamm Bowel Dis. 2011;17:2287–2294.CrossRefPubMed Diaz-Gallo L-M, Espino-Paisán L, Fransen K, et al. Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitis. Inflamm Bowel Dis. 2011;17:2287–2294.CrossRefPubMed
22.
Zurück zum Zitat Van der Sluis M, De Koning BAE, De Bruijn ACJM, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117–129.CrossRefPubMed Van der Sluis M, De Koning BAE, De Bruijn ACJM, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117–129.CrossRefPubMed
23.
Zurück zum Zitat Niv Y. Mucin gene expression in the intestine of ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2016;28:1241–1245.CrossRefPubMed Niv Y. Mucin gene expression in the intestine of ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2016;28:1241–1245.CrossRefPubMed
24.
Zurück zum Zitat Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet. 2011;43:43–47.CrossRefPubMed Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet. 2011;43:43–47.CrossRefPubMed
25.
Zurück zum Zitat Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464:713–720.CrossRefPubMed Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464:713–720.CrossRefPubMed
26.
Zurück zum Zitat Dubinsky MC, Kugathasan S, Kwon S, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1662–1670.CrossRefPubMed Dubinsky MC, Kugathasan S, Kwon S, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1662–1670.CrossRefPubMed
27.
Zurück zum Zitat Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn’s disease: can it find its niche? Therap Adv Gastroenterol. 2016;9:26–36.CrossRefPubMedPubMedCentral Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn’s disease: can it find its niche? Therap Adv Gastroenterol. 2016;9:26–36.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.CrossRefPubMed Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.CrossRefPubMed
29.
Zurück zum Zitat Pigneur B, Escher J, Elawad M, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013;19:2820–2828.CrossRefPubMed Pigneur B, Escher J, Elawad M, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013;19:2820–2828.CrossRefPubMed
30.
Zurück zum Zitat Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–2045.CrossRefPubMedPubMedCentral Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–2045.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Kalla R, Ventham NT, Kennedy NA, et al. MicroRNAs: new players in IBD. Gut. 2015;64:504–513.CrossRefPubMed Kalla R, Ventham NT, Kennedy NA, et al. MicroRNAs: new players in IBD. Gut. 2015;64:504–513.CrossRefPubMed
32.
Zurück zum Zitat Imhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67:108–119.CrossRefPubMed Imhann F, Vich Vila A, Bonder MJ, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67:108–119.CrossRefPubMed
33.
Zurück zum Zitat Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62:1505–1510.CrossRefPubMed Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62:1505–1510.CrossRefPubMed
34.
Zurück zum Zitat Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel diseases: current status and the future ahead. Gastroenterology. 2014;146:1489.CrossRefPubMed Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel diseases: current status and the future ahead. Gastroenterology. 2014;146:1489.CrossRefPubMed
35.
Zurück zum Zitat Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspringʼs risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012;18:857–862.CrossRefPubMed Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspringʼs risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012;18:857–862.CrossRefPubMed
36.
Zurück zum Zitat Bruce A, Black M, Bhattacharya S. Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. Inflamm Bowel Dis. 2014;20:1217–1226.CrossRefPubMed Bruce A, Black M, Bhattacharya S. Mode of delivery and risk of inflammatory bowel disease in the offspring: systematic review and meta-analysis of observational studies. Inflamm Bowel Dis. 2014;20:1217–1226.CrossRefPubMed
37.
Zurück zum Zitat van den Elsen LWJ, Garssen J, Burcelin R, Verhasselt V. Shaping the gut microbiota by breastfeeding: the gateway to allergy prevention? Front Pediatr. 2019;7:47.CrossRefPubMedPubMedCentral van den Elsen LWJ, Garssen J, Burcelin R, Verhasselt V. Shaping the gut microbiota by breastfeeding: the gateway to allergy prevention? Front Pediatr. 2019;7:47.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325–333.CrossRefPubMed Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325–333.CrossRefPubMed
39.
Zurück zum Zitat Hansen TS, Jess T, Vind I, et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohn’s Colitis. 2011;5:577–584.CrossRef Hansen TS, Jess T, Vind I, et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohn’s Colitis. 2011;5:577–584.CrossRef
40.
Zurück zum Zitat Xu L, Lochhead P, Ko Y, et al. Systematic review with meta-analysis: breastfeeding and the risk of Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;46:780–789.CrossRefPubMedPubMedCentral Xu L, Lochhead P, Ko Y, et al. Systematic review with meta-analysis: breastfeeding and the risk of Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;46:780–789.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015;64:1063–1071.CrossRefPubMed Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015;64:1063–1071.CrossRefPubMed
42.
Zurück zum Zitat Cholapranee A, Ananthakrishnan AN. Environmental hygiene and risk of inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2016;22:2191–2199.CrossRefPubMed Cholapranee A, Ananthakrishnan AN. Environmental hygiene and risk of inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2016;22:2191–2199.CrossRefPubMed
43.
Zurück zum Zitat Wu X-W, Ji H-Z, Yang M-F, Wu L, Wang F-Y. Helicobacter pylori infection and inflammatory bowel disease in Asians: a meta-analysis. World J Gastroenterol. 2015;21:4750–4756.CrossRefPubMedPubMedCentral Wu X-W, Ji H-Z, Yang M-F, Wu L, Wang F-Y. Helicobacter pylori infection and inflammatory bowel disease in Asians: a meta-analysis. World J Gastroenterol. 2015;21:4750–4756.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Lakatos PL, Vegh Z, Lovasz BD, et al. Is Current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis. 2013;19:1010–1017.CrossRefPubMed Lakatos PL, Vegh Z, Lovasz BD, et al. Is Current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis. 2013;19:1010–1017.CrossRefPubMed
46.
Zurück zum Zitat To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117–126.CrossRefPubMed To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117–126.CrossRefPubMed
47.
Zurück zum Zitat Bergers J, Stockbrugger R, Brummer R, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: Results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology. 2005;113:337–382. Bergers J, Stockbrugger R, Brummer R, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: Results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology. 2005;113:337–382.
48.
Zurück zum Zitat Biedermann L, Brülisauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014;20:1496–1501.CrossRefPubMed Biedermann L, Brülisauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014;20:1496–1501.CrossRefPubMed
49.
Zurück zum Zitat Parian A, Limketkai B, Koh J, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut. 2017;66:1390–1397.CrossRefPubMed Parian A, Limketkai B, Koh J, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut. 2017;66:1390–1397.CrossRefPubMed
50.
Zurück zum Zitat Myrelid P, Landerholm K, Nordenvall C, Pinkney TD, Andersson RE. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–1319.CrossRefPubMed Myrelid P, Landerholm K, Nordenvall C, Pinkney TD, Andersson RE. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–1319.CrossRefPubMed
51.
Zurück zum Zitat Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.CrossRefPubMedPubMedCentral Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808–814.CrossRefPubMed Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808–814.CrossRefPubMed
53.
Zurück zum Zitat Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut. 2007;56:1387–1392.CrossRefPubMedPubMedCentral Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut. 2007;56:1387–1392.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60:49–54.CrossRefPubMed Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60:49–54.CrossRefPubMed
55.
Zurück zum Zitat Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. Scand J Gastroenterol. 2018;53:1–7.CrossRefPubMed Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. Scand J Gastroenterol. 2018;53:1–7.CrossRefPubMed
56.
Zurück zum Zitat Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62:1153–1159.CrossRefPubMed Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62:1153–1159.CrossRefPubMed
57.
Zurück zum Zitat Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol. 2016;22:895–905.CrossRefPubMedPubMedCentral Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol. 2016;22:895–905.CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776–784.CrossRefPubMed Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776–784.CrossRefPubMed
59.
Zurück zum Zitat Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased E. coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63:116–124.CrossRefPubMed Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased E. coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63:116–124.CrossRefPubMed
60.
Zurück zum Zitat Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145:970–977.CrossRefPubMed Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145:970–977.CrossRefPubMed
61.
Zurück zum Zitat Andersen V, Chan S, Luben R, et al. Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD). J Crohn’s Colitis. 2018;12:129–136.CrossRef Andersen V, Chan S, Luben R, et al. Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD). J Crohn’s Colitis. 2018;12:129–136.CrossRef
62.
Zurück zum Zitat Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRefPubMedPubMedCentral Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785.e4–1794.e4.CrossRef Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785.e4–1794.e4.CrossRef
64.
Zurück zum Zitat Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106:699–712.CrossRefPubMed Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106:699–712.CrossRefPubMed
65.
Zurück zum Zitat Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100:84–92.CrossRefPubMed Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100:84–92.CrossRefPubMed
66.
Zurück zum Zitat Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. YJCGH. 2009;7:972.e2–980.e2. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. YJCGH. 2009;7:972.e2–980.e2.
67.
Zurück zum Zitat Weersma RK, Stokkers PCF, Van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn’ s disease cohort. Gut. 2009;58:388–395.CrossRefPubMed Weersma RK, Stokkers PCF, Van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn’ s disease cohort. Gut. 2009;58:388–395.CrossRefPubMed
68.
Zurück zum Zitat Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izy374. Zhao M, Lo BZS, Vester-Andersen MK, Vind I, Bendtsen F, Burisch J. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. https://​doi.​org/​10.​1093/​ibd/​izy374.
69.
Zurück zum Zitat Ryan JD, Silverberg MS, Xu W, et al. Predicting complicated Crohn’s disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther. 2013;38:274–283.CrossRefPubMed Ryan JD, Silverberg MS, Xu W, et al. Predicting complicated Crohn’s disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther. 2013;38:274–283.CrossRefPubMed
70.
Zurück zum Zitat Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;112:1845–1853.CrossRefPubMed Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;112:1845–1853.CrossRefPubMed
71.
Zurück zum Zitat Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet (London, England). 1996;347:1212–1217.CrossRef Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet (London, England). 1996;347:1212–1217.CrossRef
72.
Zurück zum Zitat Cravo ML, Ferreira PA, Sousa P, et al. IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2014;26:26–32.CrossRefPubMed Cravo ML, Ferreira PA, Sousa P, et al. IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2014;26:26–32.CrossRefPubMed
73.
Zurück zum Zitat Ho G-T, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128:288–296.CrossRefPubMed Ho G-T, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128:288–296.CrossRefPubMed
74.
Zurück zum Zitat Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48:57–64-5. Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48:57–64-5.
75.
Zurück zum Zitat Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–1111.CrossRefPubMed Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–1111.CrossRefPubMed
76.
Zurück zum Zitat Ran Kim E, Kyung Chang Eun Ran Kim D, Kyung Chang D. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20:9872–9881. Ran Kim E, Kyung Chang Eun Ran Kim D, Kyung Chang D. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20:9872–9881.
77.
Zurück zum Zitat Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol. 2017;19:1018–1027.CrossRefPubMed Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol. 2017;19:1018–1027.CrossRefPubMed
78.
Zurück zum Zitat Sehgal R, Berg A, Polinski JI, et al. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohnʼs disease. Dis Colon Rectum. 2012;55:115–121.CrossRefPubMed Sehgal R, Berg A, Polinski JI, et al. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohnʼs disease. Dis Colon Rectum. 2012;55:115–121.CrossRefPubMed
79.
Zurück zum Zitat Fowler SA, Ananthakrishnan AN, Gardet A, et al. SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease. J Crohns Colitis. 2014;8:845–851.CrossRefPubMed Fowler SA, Ananthakrishnan AN, Gardet A, et al. SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease. J Crohns Colitis. 2014;8:845–851.CrossRefPubMed
80.
Zurück zum Zitat Germain A, Guéant R-M, Chamaillard M, Bresler L, Guéant J-L, Peyrin-Biroulet L. CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease. Dig Liv Dis. 2015;47:938–942.CrossRef Germain A, Guéant R-M, Chamaillard M, Bresler L, Guéant J-L, Peyrin-Biroulet L. CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease. Dig Liv Dis. 2015;47:938–942.CrossRef
81.
Zurück zum Zitat Maconi G, Colombo E, Sampietro GM, et al. CARD15 gene variants and risk of reoperation in Crohn’s disease patients. Am J Gastroenterol. 2009;104:2483–2491.CrossRefPubMed Maconi G, Colombo E, Sampietro GM, et al. CARD15 gene variants and risk of reoperation in Crohn’s disease patients. Am J Gastroenterol. 2009;104:2483–2491.CrossRefPubMed
82.
Zurück zum Zitat Fischer S, Kövesdi E, Magyari L, et al. IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis. World J Gastroenterol. 2017;23:447.CrossRefPubMedPubMedCentral Fischer S, Kövesdi E, Magyari L, et al. IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis. World J Gastroenterol. 2017;23:447.CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830–1840.CrossRefPubMed Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830–1840.CrossRefPubMed
84.
Zurück zum Zitat To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn’s disease. Aliment Pharmacol Ther. 2016;43:549–561.CrossRefPubMed To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn’s disease. Aliment Pharmacol Ther. 2016;43:549–561.CrossRefPubMed
85.
Zurück zum Zitat Inamdar S, Volfson A, Rosen L, Sunday S, Katz S, Sultan K. Smoking and early infliximab response in Crohn’s disease: a meta-analysis. J Crohn’s Colitis. 2015;9:140–146.CrossRef Inamdar S, Volfson A, Rosen L, Sunday S, Katz S, Sultan K. Smoking and early infliximab response in Crohn’s disease: a meta-analysis. J Crohn’s Colitis. 2015;9:140–146.CrossRef
86.
Zurück zum Zitat Höie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–1701.CrossRefPubMed Höie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–1701.CrossRefPubMed
87.
Zurück zum Zitat Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1998;114:1143–1150. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1998;114:1143–1150.
88.
Zurück zum Zitat Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150:1561.e1–1567.e1.CrossRef Khalili H, Granath F, Smedby KE, et al. Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology. 2016;150:1561.e1–1567.e1.CrossRef
89.
Zurück zum Zitat Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196–202.CrossRefPubMed Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196–202.CrossRefPubMed
91.
Zurück zum Zitat Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin Gastroenterol Hepatol. 2016;14:1130–1136.CrossRefPubMed Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin Gastroenterol Hepatol. 2016;14:1130–1136.CrossRefPubMed
92.
Zurück zum Zitat Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563–573.CrossRefPubMed Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563–573.CrossRefPubMed
93.
Zurück zum Zitat Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low serum vitamin d during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15:240.e1–246.e1. Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low serum vitamin d during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15:240.e1–246.e1.
94.
Zurück zum Zitat Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142:482–489.CrossRefPubMed Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142:482–489.CrossRefPubMed
95.
Zurück zum Zitat Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. J Crohn’s Colitis. 2012;50:152–156. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. J Crohn’s Colitis. 2012;50:152–156.
96.
Zurück zum Zitat Torres J, Burisch J, Riddle M, Dubinsky M, Colombel J-F. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut. 2016;65:1061–1069.CrossRefPubMed Torres J, Burisch J, Riddle M, Dubinsky M, Colombel J-F. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut. 2016;65:1061–1069.CrossRefPubMed
97.
Zurück zum Zitat Nunes T, Etchevers MJ, García-Sánchez V, et al. Impact of smoking cessation on the clinical course of Crohn’s disease under current therapeutic algorithms: a multicenter prospective study. Am J Gastroenterol. 2016;111:411–419.CrossRefPubMed Nunes T, Etchevers MJ, García-Sánchez V, et al. Impact of smoking cessation on the clinical course of Crohn’s disease under current therapeutic algorithms: a multicenter prospective study. Am J Gastroenterol. 2016;111:411–419.CrossRefPubMed
98.
Zurück zum Zitat Cosnes J, Beaugerie L, Carbonnel F, Gendre J-P. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–1099.CrossRefPubMed Cosnes J, Beaugerie L, Carbonnel F, Gendre J-P. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–1099.CrossRefPubMed
99.
Zurück zum Zitat Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.CrossRefPubMed Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.CrossRefPubMed
100.
Zurück zum Zitat Durães C, Machado JC, Portela F, et al. Phenotype–genotype profiles in Crohnʼs disease predicted by genetic markers in autophagy-related genes (GOIA Study II). Inflamm Bowel Dis. 2013;19:230–239.CrossRefPubMed Durães C, Machado JC, Portela F, et al. Phenotype–genotype profiles in Crohnʼs disease predicted by genetic markers in autophagy-related genes (GOIA Study II). Inflamm Bowel Dis. 2013;19:230–239.CrossRefPubMed
101.
Zurück zum Zitat Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2005;22:613–626.CrossRefPubMed Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2005;22:613–626.CrossRefPubMed
102.
Zurück zum Zitat Netz U, Carter JV, Eichenberger MR, et al. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol. 2017;23:4958.CrossRefPubMedPubMedCentral Netz U, Carter JV, Eichenberger MR, et al. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol. 2017;23:4958.CrossRefPubMedPubMedCentral
103.
Zurück zum Zitat Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology. 2002;123:106–111.CrossRefPubMed Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology. 2002;123:106–111.CrossRefPubMed
104.
Zurück zum Zitat Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–1819.CrossRefPubMed Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–1819.CrossRefPubMed
105.
Zurück zum Zitat Bek S, Nielsen JV, Bojesen AB, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554–567.CrossRefPubMedPubMedCentral Bek S, Nielsen JV, Bojesen AB, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554–567.CrossRefPubMedPubMedCentral
106.
Zurück zum Zitat Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–1619.CrossRefPubMed Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–1619.CrossRefPubMed
107.
Zurück zum Zitat Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NF k B signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526–534.CrossRefPubMed Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NF k B signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526–534.CrossRefPubMed
Metadaten
Titel
Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease
verfasst von
Mirabella Zhao
Johan Burisch
Publikationsdatum
09.05.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05648-w

Weitere Artikel der Ausgabe 7/2019

Digestive Diseases and Sciences 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.